Results 11 to 20 of about 4,897,809 (228)

Fibroblast activation protein (FAP) as a novel metabolic target [PDF]

Molecular Metabolism, 2016
Objective: Fibroblast activation protein (FAP) is a serine protease belonging to a S9B prolyl oligopeptidase subfamily. This enzyme has been implicated in cancer development and recently reported to regulate degradation of FGF21, a potent metabolic ...
Miguel Angel Sánchez-Garrido, Kirk M. Habegger, Christoffer Clemmensen, Cassie Holleman, Timo D. Müller, Diego Perez-Tilve, Pengyun Li, Archita S. Agrawal, Brian Finan, Daniel J. Drucker, Matthias H. Tschöp, Richard D. DiMarchi, Alexei Kharitonenkov   +12 more
doaj   +6 more sources

Radioligands Targeting Fibroblast Activation Protein (FAP). [PDF]

Cancers (Basel), 2021
Targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts (CAFs) has attracted significant attention in nuclear medicine. Since these cells are present in most cancerous tissues and FAP is rarely expressed in healthy tissues, anti-FAP tracers have a potential as pan-tumor agents.
Lindner T, Giesel FL, Kratochwil C, Serfling SE.   +3 more
europepmc   +7 more sources

Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP). [PDF]

ACS Med Chem Lett, 2019
Fibroblast activation protein (FAP) is a proline-selective serine protease. It is hardly expressed in healthy adult tissue but upregulated in tissue remodeling sites associated with several diseases including epithelial cancer types, atherosclerosis, arthritis and fibrosis.
De Decker A, Vliegen G, Van Rompaey D, Peeraer A, Bracke A, Verckist L, Jansen K, Geiss-Friedlander R, Augustyns K, De Winter H, De Meester I, Lambeir AM, Van der Veken P.   +12 more
europepmc   +8 more sources

The effect of tranilast on fibroblast activation protein α (FAP-α) expression in normal and keloid fibroblasts in vitro [PDF]

Przegląd Dermatologiczny, 2017
Introduction . Tranilast (N-(3’,4’-demethoxycinnamoyl)-anthranilic acid) is an anti-allergic drug. Its mechanism of action is based on the inhibition of antigen-induced release of chemical mediators from mast cells and basophils.
Paweł P. Antończak, Magdalena Jurzak, Katarzyna Adamczyk, Agnieszka Garncarczyk, Magdalena Hartman-Petrycka   +4 more
doaj   +3 more sources

Selective Activity-Based Probes Targeting Fibroblast Activation Protein (FAP) [PDF]

Proceedings, 2019
Fibroblast activation protein (FAP) is a type II transmembrane serine protease that belongs tothe dipeptidyl peptidase (DPP) family. [...]
Johannes Vrijdag, Anvesh Jallapally, An De Decker, Koen Janssen, Filipe Elvas, Steven Staelens, Ingrid De Meester, Koen Augustyns, Anne-Marie Lambeir, Pieter Van der Veken   +9 more
doaj   +3 more sources

Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma [PDF]

ImmunoTargets and Therapy, 2021
Reyisa Bughda, Paraskevi Dimou, Reena R D’Souza, Astero Klampatsa Division of Cancer Therapeutics, The Institute of Cancer Research, London, UKCorrespondence: Astero KlampatsaThoracic Oncology Immunotherapy Group, Division of Cancer Therapeutics, The ...
Bughda R, Dimou P, D'Souza RR, Klampatsa A   +3 more
doaj   +4 more sources

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review. [PDF]

Cancers (Basel), 2020
Small molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. The purpose of this systematic review is therefore to summarize the evidence that has been gathered to ...
Windisch P, Zwahlen DR, Koerber SA, Giesel FL, Debus J, Haberkorn U, Adeberg S.   +6 more
europepmc   +3 more sources

Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma [PDF]

Radiotherapy and Oncology, 2020
Fibroblast Activation Protein (FAP)-specific Positron Emission Tomography (PET) has shown promising results in various cancers. This pilot study compares FAP-specific PET to MRI for treatment planning in 13 Glioblastoma patients. The resulting incongruent volumes could provide additional information for radiotherapy or biopsy planning.
Paul Windisch, Manuel Röhrich, Sebastian Regnery, Eric Tonndorf-Martini, Thomas Held, Kristin Lang, Denise Bernhardt, Stefan Rieken, Frederik Giesel, Uwe Haberkorn, Jürgen Debus, Sebastian Adeberg   +11 more
openaire   +5 more sources

Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy [PDF]

Clinical & Translational Immunology, 2020
Objectives Targeted immunotherapies such as chimeric antigen receptor (CAR)‐T cells are emerging as attractive treatment options for glioblastoma, but rely on identification of a suitable tumor antigen. We validated a new target antigen for glioblastoma,
Lisa M Ebert, Wenbo Yu, Tessa Gargett, John Toubia, Paris M Kollis, Melinda N Tea, Brenton W Ebert, Cedric Bardy, Mark van den Hurk, Claudine S Bonder, Jim Manavis, Kathleen S Ensbey, Mariana Oksdath Mansilla, Kaitlin G Scheer, Sally L Perrin, Rebecca J Ormsby, Santosh Poonnoose, Barbara Koszyca, Stuart M Pitson, Bryan W Day, Guillermo A Gomez, Michael P Brown   +21 more
doaj   +2 more sources

Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold

Med. Chem. Commun., 2014
The first selective, non-peptide derived inhibitors of FAP are presented.
Jansen, Koen, De Winter, Hans, Heirbaut, Leen, Cheng, Jonathan D., Joossens, Jurgen, Lambeir, Anne-Marie, De Meester, Ingrid, Augustyns, Koen, van der Veken, Pieter   +8 more
openaire   +3 more sources